Patents Assigned to Novagali Pharma SA
-
Publication number: 20130337019Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.Type: ApplicationFiled: August 2, 2013Publication date: December 19, 2013Applicant: NOVAGALI PHARMA SAInventors: LAURA RABINOVICH-GUILATT, GREGORY LAMBERT, FREDERIC LALLEMAND, BETTY PHILIPS
-
Patent number: 8524779Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.Type: GrantFiled: April 28, 2011Date of Patent: September 3, 2013Assignee: Novagali Pharma SAInventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Patent number: 8512687Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.Type: GrantFiled: July 29, 2010Date of Patent: August 20, 2013Assignee: Novagali Pharma SAInventors: Grégory Lambert, Laura Rabinovich-Guilatt, Frédéric Lallemand, Jean-Sébastien Garrigue, Betty Philips
-
Publication number: 20130164285Abstract: The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.Type: ApplicationFiled: September 2, 2011Publication date: June 27, 2013Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Jean-Sebastien Garrigue, Betty Philips
-
Patent number: 8372434Abstract: An ophthalmic oil-in-water type emulsion, which includes colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent, at least one no ionic surfactant, the emulsion having a positive zeta potential and meeting zeta potential stability Test A requirements. Process for making the emulsions. Delivery device selected from the group including lenses, ocular patch, implant, insert, the device containing an emulsion according to the invention.Type: GrantFiled: October 10, 2005Date of Patent: February 12, 2013Assignee: Novagali Pharma SAInventors: Séverine Bague, Betty Philips, Laura Rabinovich-Guilatt, Gregory Lambert, Jean-Sébastien Garrigue
-
Patent number: 8298569Abstract: Ophthalmic oil-in-water emulsions, which comprises colloid particles having an oily core surrounded by an interfacial film, the emulsion comprising an 10 immunosuppressive agent, an oil, preferably at least 50% of which being MCT, and tyloxapol. Use of such an emulsion for the manufacture of medicament for treatment of eye conditions, particularly of dry eye diseases.Type: GrantFiled: October 10, 2005Date of Patent: October 30, 2012Assignee: Novagali Pharma SAInventors: Betty Philips, Severine Bague, Laura Rabinovich-Guilatt, Gregory Lambert
-
Patent number: 8298568Abstract: A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.Type: GrantFiled: November 18, 2004Date of Patent: October 30, 2012Assignee: Novagali Pharma SAInventors: Séverine Bague, Betty Philips, Jean-Sébastien Garrigue, Laura Rabinovich-Guilatt, Gregory Lambert
-
Publication number: 20120238536Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.Type: ApplicationFiled: November 19, 2010Publication date: September 20, 2012Applicant: NOVAGALI PHARMA SAInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Jeffrey Heier
-
Publication number: 20120225939Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.Type: ApplicationFiled: November 19, 2010Publication date: September 6, 2012Applicant: NOVAGALI PHARMA SAInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
-
Patent number: 8227452Abstract: Use of a composition comprising at least one prodrug of a steroid, preferably of a corticosteroid, for the preparation of an ophthalmic composition intended for the treatment of an ocular condition or disease of a human being or an animal.Type: GrantFiled: June 1, 2007Date of Patent: July 24, 2012Assignee: Novagali Pharma SAInventors: Laura Rabinovich-Guilatt, Gregory Lambert
-
Publication number: 20120058187Abstract: A composition is described herein for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. Some embodiments also relate to a pharmaceutical composition or to a medicament comprising a composition described herein, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of a composition described herein.Type: ApplicationFiled: September 3, 2010Publication date: March 8, 2012Applicant: NOVAGALI PHARMA SAInventors: Frédéric LALLEMAND, Jean-Sébastien GARRIGUE
-
Publication number: 20110319488Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: ApplicationFiled: March 4, 2010Publication date: December 29, 2011Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
-
Publication number: 20110313038Abstract: A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ?2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: ApplicationFiled: March 4, 2010Publication date: December 22, 2011Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
-
Publication number: 20110201689Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: NOVAGALI PHARMA SAInventors: Laura Rabinovich-Guilatt, Grégory Lambert, Frédéric Lallemand, Betty Philips
-
Patent number: 7973081Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.Type: GrantFiled: July 27, 2007Date of Patent: July 5, 2011Assignee: Novagali Pharma SAInventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Publication number: 20110021443Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.Type: ApplicationFiled: July 29, 2010Publication date: January 27, 2011Applicant: NOVAGALI PHARMA SAInventors: Grégory LAMBERT, Laura RABINOVICH-GUILATT, Frédéric LALLEMAND, Jean-Sébastien GARRIGUE, Betty PHILIPS
-
Patent number: 7834172Abstract: Composition comprising at least one nucleosidic moiety and cetalkonium chloride and pharmaceutical use thereof for prevention, treatment or relief of eye, lung, and/or respiratory tract conditions.Type: GrantFiled: November 14, 2007Date of Patent: November 16, 2010Assignee: Novagali Pharma SAInventors: Gregory Lambert, Frederic Lallemand
-
Publication number: 20100286065Abstract: The present invention relates to a new therapeutic approach for the treatment of eye diseases or conditions that allows for the delivery of corticosteroids to the eye's surface but does not cause any of the usual side effects associated with topical administration of corticosteroids. More specifically, the present invention provides methods of treatment involving the administration of a corticosteroid prodrug, such as dexamethasone palmitate, to the surface of the eye. Also provided are pharmaceutical compositions and kits for carrying out such methods of treatment.Type: ApplicationFiled: December 3, 2008Publication date: November 11, 2010Applicant: NOVAGALI PHARMA SAInventors: Gregory Lambert, Laura Rabinovich, Frederic Lallemand, Betty Philips
-
Patent number: 7705186Abstract: Process for the preparation of unsaturated and saturated primary fatty amines comprising the steps of chlorination, treatment by ammonia, reduction and purification.Type: GrantFiled: July 21, 2006Date of Patent: April 27, 2010Assignee: Novagali Pharma SAInventor: Scott Gibson
-
Publication number: 20090170944Abstract: This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16, wherein the pharmaceutically active substance exhibits an improved stability. In particular, a composition is provided that comprises cetalkonium chloride micelles incorporating the prostaglanding-like therapeutic agent, latanoprost. This invention also relates to ophthalmic compositions containing such micellar compositions and methods of using these ophthalmic compositions for the treatment of eye conditions.Type: ApplicationFiled: January 2, 2008Publication date: July 2, 2009Applicant: NOVAGALI PHARMA SAInventors: Gregory Lambert, Frederic Lallemand, Laura Rabinovich-Guilatt, Severine Bague, Jean-Sebastien Garrigue